Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Celltrion Inc (068270)
Celltrion Inc stock price live, this page displays KS 068270 stock exchange data. View the 068270 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Celltrion Inc real time stock price chart below.
What Is the Celltrion Inc Stock Price Today?
The Celltrion Inc stock price today is 175,200.
What Is the Stock Symbol for Celltrion Inc?
The stock symbol for Celltrion Inc is "068270."
What Stock Exchange Does Celltrion Inc Trade On?
Celltrion Inc is listed and trades on the Seoul stock exchange.
Is Celltrion Inc a Good Stock to Buy?
Determining whether Celltrion Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 068270 quote. (ISIN: KR7068270008)
What Is the Celltrion Inc Stock Price Today?
The Celltrion Inc stock price today is 175,200.
What Is the Stock Symbol for Celltrion Inc?
The stock symbol for Celltrion Inc is "068270."
What Stock Exchange Does Celltrion Inc Trade On?
Celltrion Inc is listed and trades on the Seoul stock exchange.
Is Celltrion Inc a Good Stock to Buy?
Determining whether Celltrion Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 068270 quote. (ISIN: KR7068270008)
Seoul
Currency in KRW
175,200
+2,100(+1.21%)
Closed·
Fair Value
An estimate of a Celltrion's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
172,700
179,200
52 wk Range
158,500
239,048
068270 is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a Celltrion's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
172,700179,200
52 wk Range
158,500239,048
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.41%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.41%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
068270 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Celltrion's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
256,665
Upside
+46.50%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
22 Buy
2 Hold
0 Sell
Ratings:
24 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 256,665
(+46.50% Upside)
Earnings
Latest Release
Jul 03, 2026
EPS / Forecast
1,351.86 / 1,450.54
Revenue / Forecast
1.31T / 1.24T
Compare 068270 to Peers and Sector
Metrics to compare | 068270 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship068270PeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.7x | 21.4x | −0.4x | |
PEG Ratio | 0.21 | 0.06 | 0.00 | |
Price/Book | 2.3x | 1.6x | 2.6x | |
Price / LTM Sales | 9.0x | 3.0x | 3.0x | |
Upside (Analyst Target) | 48.4% | 41.4% | 51.5% | |
Fair Value Upside | Unlock | 14.4% | 8.8% | Unlock |
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Celltrion (068270) Stock Price Today?
The Celltrion stock price today is 175,200 KRW.
What Stock Exchange Does Celltrion Trade On?
Celltrion is listed and trades on the Seoul Stock Exchange.
What Is the Stock Symbol for Celltrion?
The stock symbol for Celltrion is "068270."
What Is the Celltrion Market Cap?
As of today, Celltrion market cap is 40.18T KRW.
What Is Celltrion's Earnings Per Share (TTM)?
The Celltrion EPS (TTM) is 5,486.
When Is the Next Celltrion Earnings Date?
Celltrion will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is 068270 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Celltrion Stock Split?
Celltrion has split 19 times.
How Many Employees Does Celltrion Have?
Celltrion has 2680 employees.
What is the current trading status of Celltrion (068270)?
As of Jul 11, 2026, Celltrion (068270) is trading at a price of 175,200 KRW, with a previous close of 173,100 KRW. The stock has fluctuated within a day range of 172,700 KRW to 179,200 KRW, while its 52-week range spans from 158,500 KRW to 239,048 KRW.
What Is Celltrion (068270) Price Target According to Analysts?
The average 12-month price target for Celltrion is 256,665 KRW, with a high estimate of 280000 KRW and a low estimate of 190476.19048 KRW. 22 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +46.50% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.